DENVER, April 15, 2015 (GLOBE NEWSWIRE) -- Islet Holdings, Inc. (OTC:ISHI) ("the Company") recently announced they would expand their business plan to pursue new medical technologies and products based around development, production, and sales of cannabidiol (CBD) oil. CBD is one of approximately 85 cannabinoids present in the Cannabis plant. A British study recently suggested that cultivation of Cannabis plants rich in Cannabidiol (CBD) and other phenolic substances would be useful for medicinal purposes in the treatment of certain inflammatory disorders. In this study, "CBD was found to be more effective than aspirin as an anti-inflammatory agent."
Pre-clinical studies suggest that CBD may have therapeutic benefits in the treatment of various conditions, including chronic pain, anxiety, nausea, rheumatoid arthritis, schizophrenia, diabetes, PTSD, alcoholism, strokes, cardiovascular disease, cancer, and other ailments. CBD has been shown to suppress colon cancer tumors in mice and to kill breast cancer cells in lab studies by Dr. Sean McAllister at the California Pacific Medical Center. CBD also has been shown to have anti-inflammatory, neuro-protective, and anti-oxidant properties. The Hemp Industries Association (HIA) reports that the value of hemp-based food, supplements, and body care sales in the United States totaled $184 million in 2013.
Islet Holdings, Inc. recently signed a Worldwide Exclusive License with Apollon Formularies, Inc. ("Apollon") to purchase high quality industrial hemp cannabidiol ("CBD") and hemp oil for all of the CBD based Islet products in the fields of nutraceuticals, health, and wellness. Apollon will certify each crop as Industrial Hemp and will perform required Quality Control on the plants, the oil, and the CBD produced from these plants. Under this Worldwide Exclusive License, Apollon will agree not to sell CBD or hemp oil to any company with products similar to or competitive with any Islet CBD based products
Under the terms of the Exclusive Agreement, Apollon guarantees to Islet "Most Favored Nation" pricing for Apollon grown CBD and hemp oil and all associated deliverable products with this guaranteed special pricing for the next three years. In addition to the CBD and hemp oil, this agreement includes the following industrial hemp CBD based deliverables produced by Apollon for Islet: oral dis-solvable film strips, oral 1 oz flavored shots, pre-loaded vape cartridges, sub-lingual sprays, and trans dermal patches.
Islet Holdings, Inc. also recently signed a Worldwide Exclusive License with Last Call Ventures, Inc. ("Last Call") to have Last Call provide and utilize their unique and great tasting flavor system for specifically flavoring the Islet industrial hemp derived CBD and hemp oil products including the flavored 1 oz oral shots, flavored vape oils, flavored sub-lingual sprays and flavored oral dis-solvable film strips.
In addition, Last Call will use its proprietary special chemistry expertise to produce these products for Islet Holdings, Inc., using cannabidiol ("CBD") and hemp oil that will keep the active ingredients in solution for a much longer shelf life. Last Call guaranteed to Islet "Most Favored Nation" pricing for Last Call produced flavors for all of the CBD (and hemp oil) based Islet products. This Islet special price will be guaranteed for the next three years.
Apollon and Last Call will use their best efforts to assist Islet in developing an intellectual property portfolio of patents and trademarks in the Field of Use of Industrial Hemp compounds, components, genetics, and products using state-of-the-art artificial intelligence techniques. This patent portfolio in the Field of Use of Industrial Hemp will be fully assigned to and owned by Islet.
"We are especially pleased to have Apollon and Last Call as our partners to produce and commercialize a high quality, low cost, great tasting branded line of CBD based nutraceutical products," stated J. Michael Heil, Director and CEO of the Islet Holdings, Inc. "In addition, we intend, with the assistance of Apollon and Last Call to create a valuable blocking patent portfolio to protect the formulations in our products."
Stephen D. Barnhill, MD, Chairman and CEO of Apollon Formularies, Inc. and a renowned expert in the field of artificial intelligence techniques applied to medical discovery stated, "It is very exciting to be working with the Islet and Last Call teams to create and patent protect the Islet brand of scientifically formulated nutraceutical products for the rapidly growing functional beverage market."
Release Note: Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. The realization of any or all of these expectations is subject to a number of risks and uncertainties and it is possible that the assumptions made by management may not materialize.
Safe Harbor Statement: This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as ISHI or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements
CONTACT: Islet Corporate Information at 303-587-1435Source:Islet Holdings, Inc.